List of Excipients in API bictegravir/lenacapavir
Excipients in NDA-approved (novel) drugs containing bictegravir/lenacapavir
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Gilead Sciences Inc | BIXLENVO | bictegravir/lenacapavir | 61958-3601 | CELLULOSE, MICROCRYSTALLINE | 2035-06-19 |
| Gilead Sciences Inc | BIXLENVO | bictegravir/lenacapavir | 61958-3601 | COPOVIDONE K25-31 | 2035-06-19 |
| Gilead Sciences Inc | BIXLENVO | bictegravir/lenacapavir | 61958-3601 | CROSCARMELLOSE SODIUM | 2035-06-19 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for bictegravir/lenacapavir
Excipient focus: CELLULOSE, MICROCRYSTALLINE
bictegravir/lenacapavir drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | bictegravir/lenacapavir | 61958-3601 |
| >Company | >Ingredient | >NDC |
bictegravir/lenacapavir drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: COPOVIDONE K25-31
bictegravir/lenacapavir drug variants containing COPOVIDONE K25-31
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | bictegravir/lenacapavir | 61958-3601 |
| >Company | >Ingredient | >NDC |
bictegravir/lenacapavir drug variants not containing COPOVIDONE K25-31
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
bictegravir/lenacapavir drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | bictegravir/lenacapavir | 61958-3601 |
| >Company | >Ingredient | >NDC |
bictegravir/lenacapavir drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
bictegravir/lenacapavir drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | bictegravir/lenacapavir | 61958-3601 |
| >Company | >Ingredient | >NDC |
bictegravir/lenacapavir drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
bictegravir/lenacapavir drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | bictegravir/lenacapavir | 61958-3601 |
| >Company | >Ingredient | >NDC |
bictegravir/lenacapavir drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
bictegravir/lenacapavir drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | bictegravir/lenacapavir | 61958-3601 |
| >Company | >Ingredient | >NDC |
bictegravir/lenacapavir drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLOXAMER 407
bictegravir/lenacapavir drug variants containing POLOXAMER 407
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | bictegravir/lenacapavir | 61958-3601 |
| >Company | >Ingredient | >NDC |
bictegravir/lenacapavir drug variants not containing POLOXAMER 407
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
bictegravir/lenacapavir drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | bictegravir/lenacapavir | 61958-3601 |
| >Company | >Ingredient | >NDC |
bictegravir/lenacapavir drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
bictegravir/lenacapavir drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | bictegravir/lenacapavir | 61958-3601 |
| >Company | >Ingredient | >NDC |
bictegravir/lenacapavir drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
bictegravir/lenacapavir drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | bictegravir/lenacapavir | 61958-3601 |
| >Company | >Ingredient | >NDC |
bictegravir/lenacapavir drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
bictegravir/lenacapavir drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | bictegravir/lenacapavir | 61958-3601 |
| >Company | >Ingredient | >NDC |
bictegravir/lenacapavir drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch